Literature DB >> 18308465

Biology of somatostatin in breast cancer.

Heather L Watt1, G Kharmate, Ujendra Kumar.   

Abstract

The biological effects of the neuropeptide somatostatin (SST) are mediated via a family of five somatostatin receptors (SSTRs) belonging to a family of G-protein-coupled receptors (GPCRs). SSTR regulate the secretion of hormones, growth factors, neurotransmission and cell growth in receptor-specific manner. In addition, SST plays an inhibitory role in several mammary cancer models. These effects are mediated both indirectly through inhibition of hormones and growth factors which promote tumor growth as well as directly via SSTRs present on tumor cells to inhibit mitogenic signaling of growth factor receptor kinases leading to growth arrest and induction of apoptosis. Here, we present an overview on the role of SST and its analogs in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308465     DOI: 10.1016/j.mce.2008.01.006

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  15 in total

1.  Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells.

Authors:  Yuan Zhang; Xueqing Wang; Jiancheng Wang; Xuan Zhang; Qiang Zhang
Journal:  Pharm Res       Date:  2011-02-22       Impact factor: 4.200

2.  The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells.

Authors:  Yong He; Xiao-Mei Yuan; Ping Lei; Sha Wu; Wei Xing; Xiao-Li Lan; Hui-Fen Zhu; Tao Huang; Guo-Bing Wang; Rui An; Yong-Xue Zhang; Guan-Xin Shen
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

3.  Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors.

Authors:  Rishi K Somvanshi; Ujendra Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2012-04-27

4.  The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.

Authors:  Ozan Balakan; Mehmet Emin Kalender; Ali Suner; Beyhan Cengiz; Serdar Oztuzcu; Recep Bayraktar; Ersin Borazan; Taner Babacan; Celaletdin Camci
Journal:  Med Sci Monit       Date:  2014-08-12

Review 5.  Somatostatin analogues labeled with copper radioisotopes: current status.

Authors:  Aleksandra Marciniak; Justyna Brasuń
Journal:  J Radioanal Nucl Chem       Date:  2017-06-13       Impact factor: 1.371

Review 6.  Somatostatin receptors as a new active targeting sites for nanoparticles.

Authors:  Ahmed A H Abdellatif; Sa'ed M Aldalaen; Waleed Faisal; Hesham M Tawfeek
Journal:  Saudi Pharm J       Date:  2018-05-31       Impact factor: 4.330

7.  Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.

Authors:  Céline Kerros; Thibault Cavey; Brigitte Sola; Philippe Jauzac; Stéphane Allouche
Journal:  J Exp Clin Cancer Res       Date:  2009-06-07

8.  Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode.

Authors:  Raúl M Luque; Alicia Villa-Osaba; Fernando L-López; Ana I Pozo-Salas; Rafael Sánchez-Sánchez; Rosa Ortega-Salas; Luis de Lecea; Marina Álvarez-Benito; José López-Miranda; Manuel D Gahete; Justo P Castaño
Journal:  Breast Cancer Res       Date:  2016-03-08       Impact factor: 6.466

9.  Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.

Authors:  Xi Chen; Xiao-Yu Zhang; Yang Shen; Li-Li Fan; Mu-Lan Ren; Yong-Ping Wu
Journal:  Oncotarget       Date:  2016-12-13

10.  The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.

Authors:  Manuel D Gahete; David Rincón-Fernández; Mario Durán-Prado; Marta Hergueta-Redondo; Alejandro Ibáñez-Costa; Alejandro Rojo-Sebastián; Francisco Gracia-Navarro; Michael D Culler; Oriol Casanovas; Gema Moreno-Bueno; Raúl M Luque; Justo P Castaño
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.